Search Results - "Ethell, Mark"

Impact of Ultra High‐risk Genetics on Real‐world Outcomes of Transplant‐eligible Multiple Myeloma Patients by Panopoulou, Aikaterini, Easdale, Sandra, Ethell, Mark, Nicholson, Emma, Potter, Mike, Giotas, Asterios, Woods, Helena, Thornton, Tracy, Pawlyn, Charlotte, Boyd, Kevin D., Kaiser, Martin F.

“…Refined prediction of early relapse following standard‐of‐care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could…”
Get full text

The impact of extramedullary disease at presentation on the outcome of myeloma by Wu, Ping, Davies, Faith E., Boyd, Kevin, Thomas, Karen, Dines, Sharon, Saso, Radovan M., Potter, Mike N., Ethell, Mark E., Shaw, Bronwen E., Morgan, Gareth J.

“…This study was conducted to compare the presenting features and outcome of newly-diagnosed myeloma with and without extramedullary (EM) manifestations and to…”
Get full text

Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital by Gleeson, Mary, Peckitt, Clare, Cunningham, David, Gibb, Adam, Hawkes, Eliza A., Back, Morgan, Yasar, Binnaz, Foley, Kate, Lee, Rebecca, Dash, Joanna, Johnson, Hannah, O'Hara, Catherine, Wotherspoon, Andrew, Attygalle, Ayoma, Menasce, Lia, Shenjere, Patrick, Potter, Mike, Ethell, Mark E., Dearden, Claire, Radford, John, Chau, Ian, Linton, Kim

“…We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One…”
Get full text

The feasibility of plerixafor as a second-line stem cell mobilizing agent in children by Aabideen, Kanakkande, Anoop, Parameswaran, Ethell, Mark E, Potter, Mike N

“…In patients heavily pretreated with myelosuppressive chemotherapy or irradiation, Granulocyte colony stimulating factor (G-CSF) may fail to mobilize stem cells…”
Get full text

Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients by Sriskandarajah, Priya, Webb, Katharine, Chisholm, David, Raobaikady, Ravi, Davis, Kim, Pepper, Natalie, Ethell, Mark E, Potter, Mike N, Shaw, Bronwen E

“…The introduction of central venous catheters has advanced medical care, particularly in hemato-oncology. However these can be associated with an increased…”
Get full text

High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD by Dignan, Fiona L., Potter, Mike N., Ethell, Mark E., Taylor, Matthew, Lewis, Lily, Brennan, Joy, McNamara, Louise, Evans, Steve O., Riley, Unell, Davies, Faith E., Dearden, Claire E., Morgan, Gareth J., Shaw, Bronwen E.

“…Graft‐versus‐host disease (GvHD) is a common complication following haematopoietic stem cell transplant but little is published about the impact of this…”
Get full text

First report of fatal human infections with the cactophilic yeast Sporopachydermia cereana by Anoop, Parameswaran, Riley, Unell, Ethell, Mark E, Treleaven, Jennie, Johnson, Elizabeth M, Morgan, Gareth J, Potter, Mike N

“…Summary Sporopachydermia cereana is a cactophilic yeast, which is not recognised as a human pathogen. We describe two fatal infections with this fungus in…”
Get full text

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis by Wu, Ping, Davies, Faith E., Horton, Clive, Jenner, Matthew W., Krishnan, Biju, Alvares, Caroline L., Saso, Radovan, Mccormack, Rita, Dines, Sharon, Treleaven, Jennifer G., Potter, Michael N., Ethell, Mark E., Morgan, Gareth J

“…A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP…”
Get full text

An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia by Mohammed, Kabir, Dignan, Fiona, Ethell, Mark E., Davies, Faith E., Morgan, Gareth J., Riley, Unell, Evans, Steve, Potter, Michael N., Shaw, Bronwen E.

Get full text

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE by Srikanth, Muralikrishnan, Davies, Faith E., Wu, Ping, Jenner, Matthew W., Ethell, Mark E., Potter, Michael N., Shaw, Bronwen E., Saso, Radovan M., Dines, Sharon, Morgan, Gareth J.

“…Blastoid morphology is a rare presenting feature of myeloma which is frequently seen in patients with extramedullary myeloma and is associated with poor…”
Get full text

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments by Alvares, Caroline L., Davies, Faith E., Horton, Clive, Patel, Gita, Powles, Ray, Sirohi, Bhawna, Zuha, Roslin, Gatt, Alex, Saso, Radovan, Treleaven, Jennifer G., Dearden, Claire E., Potter, Michael N., Ethell, Mark E., Morgan, Gareth J.

“…Summary Induction chemotherapy followed by high‐dose melphalan (HDM) is the standard treatment for fitter patients with myeloma. The place of bortezomib and…”
Get full text

Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis by Anoop, Parameswaran, Shaw, Bronwen E, Riley, Unell, Ethell, Mark E, Taj, Mary, Lancaster, Donna L, Atra, Ayad, Saso, Radovan, Littlewood, Simon, Mohammed, Kabir, Davies, Faith, Treleaven, Jennie, Morgan, Gareth J, Potter, Mike N

“…Viral haemorrhagic cystitis (HC) is a significant complication after haematopoietic stem cell transplantation (HSCT), with a potential for major morbidity. The…”
Get more information

RELAPSE OF PRIMITIVE MEDIASTINAL LYMPHOMA AS A MYELOID MASS FOLLOWING BEAM AUTOLOGOUS TRANSPLANT AND SUBSEQUENT REFRACTORINESS TO MATCHED UNRELATED UMBILICAL CORD BLOOD ALLOGRAFT by Anoop, Parameswaran, Lancaster, Donna L., Ethell, Mark E., Potter, Mike N., Wotherspoon, Andrew

“…Outlining the treatment for an unclassifiable lymphoid malignancy is often difficult. A highly undifferentiated lymphomatous mass that relapsed in spite of…”
Get full text

Venetoclax-based salvage for management of relapsed acute leukaemia after allogeneic haematopoetic stem cell transplant: durable remissions only seen following consolidation with donor lymphocyte infusion or second transplant by Smith, Katy, Fathoala, Dina, Anthias, Chloe, Easdale, Sandra, Ethell, Mark, Mir, Farheen, Pickard, Lucy, Potter, Mike, Taussig, David, Nicholson, Emma

Get full text

In Vitro Elution of Gentamicin, Amikacin, and Ceftiofur From Polymethylmethacrylate and Hydroxyapatite Cement by Ethell, Mark T., Bennett, R. Avery, Brown, Murray P., Merritt, Kelly, Davidson, Jeffrey S., Tran, Thang

“…Objective— To compare the elution characteristics of ceftiofur and liquid and powdered gentamicin and amikacin from polymethylmethacrylate (PMMA) and from…”
Get full text

Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee by McLornan, Donal P., Czerw, Tomasz, Damaj, Gandhi, Ethell, Mark, Gurnari, Carmelo, Hernández-Boluda, Juan Carlos, Polverelli, Nicola, Schwaab, Juliana, Sockel, Katja, Raffaella, Greco, Onida, Francesco, Sánchez-Ortega, Isabel, Battipaglia, Giorgia, Elena, Chiara, Gotlib, Jason, Reiter, Andreas, Rossignol, Julien, Ustun, Celalettin, Valent, Peter, Yakoub-Agha, Ibrahim, Radia, Deepti H.

“…Systemic Mastocytosis (SM) is a multifaceted clinically heterogeneous disease. Advanced SM (AdvSM) comprises three entities: aggressive SM (ASM), mast cell…”
Get full text

Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital by Mir, Farheen, Robinson, Anna, Ethell, Mark Edward, Potter, Michael, Nicholson, Emma, Anthias, Chloe, Easdale, Sandra, Gonzalez-Arias, Carlos, Sud, Amit, Dearden, Claire E., Chau, Ian, Cunningham, David, El-Sharkawi, Dima, Sharma, Bhupinder, Iyengar, Sunil

Get full text

Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoetic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique by Durie, Emily, Nicholson, Emma, Anthias, Chloe, Dunne, Emma M., Potter, Mike, Ethell, Mark, Messiou, Christina, Brennan, Joy, Eagle, Sally, Talbot, James, Smyth, Gregory, Ingram, Westley, Saran, Frank, Mandeville, Henry C.

“…•FP IMRT has a low rate of idiopathic IP with only 4% (n = 3) CTCAE grade ≥ 3.•30% developed IP due to any cause; evidence of an underlying infective cause was…”
Get full text

No Improvement in Survival for T-PLL Patients over the Last Two Decades by Cross, Matthew J, Else, Monica, Morilla, Ricardo, Ethell, Mark Edward, Potter, Michael, El-Sharkawi, Dima, Iyengar, Sunil, Dearden, Claire E.

“…T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive, post thymic lymphoid malignancy, with an incidence of approximately 0.1/100,000 people. T-PLL…”
Get full text

Palliative care for patients around the time of haematopoietic stem cell transplant: a qualitative study of patients’ perceptions and experiences of unmet need and attitudes towards palliative care involvement by Gemmell, Rebecca, Halley, Angela, Stevens, Anna-Marie, Allam, Alison, Perkins, Margaret, Ethell, Mark, Sriskandarajah, Priya, Droney, Joanne

“…Background Haemato-oncology patients are likely to be referred later to palliative care than patients with solid tumours, despite experiencing similar symptom…”
Get full text